Investigating how Angiopoietin-2 affects liver metastasis in pancreatic neuroendocrine tumors
Official title: Angiopoietin-2/Tie2 signaling regulation of liver metastasis in pancreatic neuroendocrine tumors
Funded at Columbia University Health Sciences · NIH-10867490 · Data updated 2026-11-12
This study is looking at how a protein called Angiopoietin-2 affects the spread of pancreatic neuroendocrine tumors to the liver, and it aims to find out if blocking this protein can help slow down tumor growth and improve survival for patients with this type of cancer.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | July 12, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2024 |
| Award (this year) | $395,516 |
| NIH project number | 5R37CA266270-03 |
| Project ID | NIH-10867490 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with pancreatic neuroendocrine tumors, particularly those with or at risk of liver metastases.
✕Less likely to help
Patients with non-pancreatic tumors or those without liver metastases may not benefit from this research.
What this research studies
This research focuses on understanding the role of Angiopoietin-2 (Ang2) in the development of liver metastases in patients with pancreatic neuroendocrine tumors (PanNET). The study aims to explore how Ang2 interacts with the Tie2 receptor to influence tumor growth and immune response, particularly in the context of the immunosuppressive environment that often accompanies these tumors. By using a mouse model, researchers will investigate whether inhibiting Ang2 can reduce liver metastasis and improve patient survival. This could lead to new therapeutic strategies for managing advanced PanNET.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment options for patients with metastatic pancreatic neuroendocrine tumors.
How similar studies have gone: Preliminary studies have shown promising results with Ang2 inhibition in mouse models, suggesting potential for success in similar approaches.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Kim, Minah — Columbia University Health Sciences
- Study coordinator: Kim, Minah
Related research
Other NIH-funded projects on the same topics.
-
Angiopoietin-2 and Tie2 signals shaping liver metastasis in pancreatic neuroendocrine tumors
A study explores how Angiopoietin-2 and the Tie2 receptor influence the spread of pancreatic neuroendocrine tumors to the liver and how this affects responses to immunotherapy.
-
Targeting Angiopoietin‑2/Tie2 to limit liver spread of pancreatic neuroendocrine tumors
The team is looking at whether blocking a blood‑vessel protein called Angiopoietin‑2 can reduce liver spread in people with pancreatic neuroendocrine tumors.
-
Understanding and Stopping Liver Spread of Pancreatic Neuroendocrine Tumors
This work explores how a protein called Angiopoietin-2 helps pancreatic neuroendocrine tumors spread to the liver and how blocking it might improve treatments.
-
Understanding how Angiopoietin-2 affects liver metastasis in pancreatic neuroendocrine tumors
This study is looking at how a protein called Angiopoietin-2 affects the spread of pancreatic neuroendocrine tumors to the liver, and it hopes to find new ways to help patients with this type of cancer live longer and healthier lives.
-
Lymph node metastasis and immune tolerance in head and neck cancer
A study in people with head and neck cancer looks at how cancer spread to lymph nodes may shape the immune system and help tumors grow.
-
Targeting how RMS cells fail to mature to slow or stop pediatric muscle cancer spread
A project to understand why a pediatric muscle cancer called rhabdomyosarcoma spreads, and to test ideas that could slow or stop it by helping cancer cells mature properly.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.